Palisade Bio, Inc. (NASDAQ:PALI) Receives $8.83 Average Price Target from Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been given a consensus recommendation of “Buy” by the ten research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.00.

PALI has been the subject of several research reports. Wolfe Research assumed coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. Finally, Oppenheimer started coverage on Palisade Bio in a research note on Thursday. They issued an “outperform” rating and a $8.00 price objective on the stock.

Palisade Bio Stock Performance

NASDAQ:PALI opened at $1.95 on Monday. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.86. The company has a market cap of $338.48 million, a price-to-earnings ratio of -1.93 and a beta of 1.50. The stock has a fifty day simple moving average of $1.92 and a 200-day simple moving average of $1.89.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities research analysts predict that Palisade Bio will post -0.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert Jr. Baltera bought 25,000 shares of the stock in a transaction on Thursday, July 9th. The stock was acquired at an average cost of $1.96 per share, for a total transaction of $49,000.00. Following the acquisition, the director owned 461,904 shares of the company’s stock, valued at $905,331.84. This represents a 5.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mitchell Lawrence Jones sold 51,880 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total value of $106,354.00. Following the transaction, the insider owned 94,009 shares in the company, valued at approximately $192,718.45. This represents a 35.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders bought 125,000 shares of company stock worth $250,100. 0.07% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $28,318,000. Commodore Capital LP purchased a new stake in shares of Palisade Bio in the 4th quarter worth approximately $26,896,000. Janus Henderson Group PLC boosted its stake in shares of Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after purchasing an additional 149,118 shares in the last quarter. Octagon Capital Advisors LP increased its holdings in Palisade Bio by 7.4% during the first quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock valued at $17,984,000 after buying an additional 708,419 shares during the period. Finally, RA Capital Management L.P. purchased a new position in Palisade Bio during the fourth quarter valued at approximately $16,742,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.